DrugDashboards

Imatinib Mesylate

Imatinib Mesylate · IMATINIB MESYLATE 100 mg/1 · Tablet, Film Coated · Oral · Civica Script LLC

NDC 82249-0020-90 · 90 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00093-7629-98) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$8.96per unit
middle half $1.78–$18.50 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $8.96
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 4 · prior auth 78% · step therapy 0% · qty limit 93%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for imatinib mesylate (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,270.90 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA212975
TE code
AB
Approval date
Apr 14, 2025
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Imatinib Mesylate (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
American Health PackagingIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Apotex CorpIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Apotex CorpIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Armas Pharmaceuticals Inc.IMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Armas Pharmaceuticals Inc.IMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.IMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.IMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Civica Script LLCIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Civica Script LLCIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Quallent Pharmaceuticals Health LlcIMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Quallent Pharmaceuticals Health LlcIMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.IMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.IMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.IMATINIB MESYLATE 400 mg/1Jul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.IMATINIB MESYLATE 100 mg/1Jul 15, 2026Sep 2, 2026
BluePoint LaboratoriesIMATINIB MESYLATE 400 mg/1Jul 15, 2026Aug 31, 2026
BluePoint LaboratoriesIMATINIB MESYLATE 100 mg/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Imatinib Mesylate — NDC 82249-0020-90," retrieved September 3, 2026, https://drugdashboards.com/drug/82249002090.

Free to cite with attribution — see how the data is put together.